D. E. V. Wilman

721 total citations
29 papers, 546 citations indexed

About

D. E. V. Wilman is a scholar working on Organic Chemistry, Molecular Biology and Physical and Theoretical Chemistry. According to data from OpenAlex, D. E. V. Wilman has authored 29 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Organic Chemistry, 9 papers in Molecular Biology and 8 papers in Physical and Theoretical Chemistry. Recurrent topics in D. E. V. Wilman's work include Chemical Reactions and Mechanisms (8 papers), Synthesis and Characterization of Heterocyclic Compounds (7 papers) and Click Chemistry and Applications (4 papers). D. E. V. Wilman is often cited by papers focused on Chemical Reactions and Mechanisms (8 papers), Synthesis and Characterization of Heterocyclic Compounds (7 papers) and Click Chemistry and Applications (4 papers). D. E. V. Wilman collaborates with scholars based in United Kingdom, Canada and India. D. E. V. Wilman's co-authors include Martin R. Osborne, P.D. Lawley, Phyllis M. Goddard, T.A. Connors, W. C. J. Ross, Richard T. Wheelhouse, Malcolm F. G. Stevens, Michael Jarman, Charles Jameson and Jenny Titley and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Journal of Medicinal Chemistry and Biochemical Pharmacology.

In The Last Decade

D. E. V. Wilman

29 papers receiving 515 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. E. V. Wilman United Kingdom 12 243 240 102 74 62 29 546
R. G. WALLACE United Kingdom 8 200 0.8× 213 0.9× 31 0.3× 37 0.5× 50 0.8× 14 527
Robert J. Weinkam United States 15 134 0.6× 208 0.9× 35 0.3× 58 0.8× 15 0.2× 31 500
Leif Nørskov‐Lauritsen Denmark 12 177 0.7× 443 1.8× 63 0.6× 74 1.0× 107 1.7× 19 744
Kurt Eger Germany 18 532 2.2× 428 1.8× 18 0.2× 84 1.1× 25 0.4× 76 1.0k
Micheal D. Gaul United States 14 487 2.0× 507 2.1× 35 0.3× 81 1.1× 28 0.5× 18 1.1k
Shanthi R. Paranawithana United States 13 96 0.4× 583 2.4× 51 0.5× 141 1.9× 15 0.2× 15 735
Eva Altmann Switzerland 18 494 2.0× 691 2.9× 31 0.3× 147 2.0× 38 0.6× 39 1.1k
T. Brian H. McMurry Ireland 17 274 1.1× 540 2.3× 29 0.3× 125 1.7× 14 0.2× 87 922
Nada Zein United States 17 783 3.2× 620 2.6× 39 0.4× 147 2.0× 81 1.3× 26 1.3k
Jeffrey R. Spencer United States 16 315 1.3× 326 1.4× 28 0.3× 79 1.1× 26 0.4× 30 721

Countries citing papers authored by D. E. V. Wilman

Since Specialization
Citations

This map shows the geographic impact of D. E. V. Wilman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. E. V. Wilman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. E. V. Wilman more than expected).

Fields of papers citing papers by D. E. V. Wilman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. E. V. Wilman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. E. V. Wilman. The network helps show where D. E. V. Wilman may publish in the future.

Co-authorship network of co-authors of D. E. V. Wilman

This figure shows the co-authorship network connecting the top 25 collaborators of D. E. V. Wilman. A scholar is included among the top collaborators of D. E. V. Wilman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. E. V. Wilman. D. E. V. Wilman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wheelhouse, Richard T., Dong‐Fang Shi, D. E. V. Wilman, & Malcolm F. G. Stevens. (1996). Antitumour benzothiazoles. Part 4. An NMR study of the sites of protonation of 2-(4-aminophenyl)benzothiazoles. Journal of the Chemical Society Perkin Transactions 2. 1271–1271. 5 indexed citations
2.
Wilman, D. E. V., Brian D. Palmer, & William A. Denny. (1995). Application of 15N Nuclear Magnetic Resonance Spectroscopy to the Determination of the Stability of Aryl Nitrogen Mustards. Journal of Medicinal Chemistry. 38(12). 2256–2258. 8 indexed citations
3.
MacGillivray, Leonard R., et al.. (1995). 1-(p-Carbamoylphenyl)-3,3-dimethyltriazene, an Antitumour Agent. Acta Crystallographica Section C Crystal Structure Communications. 51(12). 2624–2627. 9 indexed citations
4.
Osborne, Martin R., D. E. V. Wilman, & P.D. Lawley. (1995). Alkylation of DNA by the Nitrogen Mustard Bis-(2-chloroethyl)methylamine. Chemical Research in Toxicology. 8(2). 316–320. 79 indexed citations
5.
Wheelhouse, Richard T., et al.. (1995). Antitumour imidazotetrazines. Part 31. The synthesis of isotopically labelled temozolomide and a multinuclear (1H, 13C, 15N) magnetic resonance investigation of temozolomide and mitozolomide. Journal of the Chemical Society Perkin Transactions 1. 249–249. 15 indexed citations
6.
Wilman, D. E. V., et al.. (1994). Novel analogues of CB 1954: Their potential use in antibody directed enzyme prodrug therapy (ADEPT). European Journal of Cancer. 30. S9–S9. 2 indexed citations
7.
8.
Smith, Timothy, C. Bush, Charles Jameson, et al.. (1993). Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR in Biomedicine. 6(5). 318–323. 41 indexed citations
9.
Neidle, Stephen & D. E. V. Wilman. (1992). X-ray studies on anti-tumour triazenes. Structures of 1-(4-carbamoylphenyl)-3,3-dimethyltriazene 1-oxide and 3,3-dimethyl-1-(4-nitrophenyl)triazene. Acta Crystallographica Section B Structural Science. 48(2). 213–217. 10 indexed citations
10.
Wilman, D. E. V.. (1990). The Chemistry of Antitumour Agents. 53 indexed citations
11.
Wilman, D. E. V.. (1990). Tumour inhibitory triazenes. 5—15N NMR study of 1‐aryl‐3,3‐dialkyltriazenes. Magnetic Resonance in Chemistry. 28(8). 729–731. 10 indexed citations
12.
Judson, Ian, A H Calvert, G. Abel, et al.. (1989). Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).. PubMed. 49(19). 5475–9. 10 indexed citations
13.
Wilman, D. E. V.. (1988). The development of a second-generation triazene. Cancer Treatment Reviews. 15(1). 69–72. 9 indexed citations
14.
Goddard, A., Rosanne M. Orr, J. A. Stock, & D. E. V. Wilman. (1987). Synthesis and ribonucleotide reductase inhibitory activity of analogues of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY).. PubMed. 2(3). 235–45. 3 indexed citations
15.
Douglas, Kenneth T., et al.. (1986). Iron and haem complexation studies of 2,3-dihydro-1H-imidazo(1,2-b)pyrazole (IMPY, NSC 51143), a tumour cell ribonucleotide reductase inhibitor.. PubMed. 1(3). 189–95. 6 indexed citations
16.
Kuroda, Reiko & D. E. V. Wilman. (1985). 3-(4-Carbamoylphenyl)-1-methyltriazene 1-oxide. Acta Crystallographica Section C Crystal Structure Communications. 41(10). 1543–1545. 3 indexed citations
17.
Wilman, D. E. V., et al.. (1984). Tumor inhibitory triazenes. 3. Dealkylation within an homologous series and its relation to antitumor activity. Journal of Medicinal Chemistry. 27(7). 870–874. 11 indexed citations
18.
19.
Connors, T.A., et al.. (1976). Tumour inhibitory triazenes: Structural requirements for an active metabolite. Biochemical Pharmacology. 25(3). 241–246. 94 indexed citations
20.
Workman, Paul, John A. Double, & D. E. V. Wilman. (1976). Enzyme activated anti-tumour agents—III. hydrolysis of conjugates of p-hydroxyaniline mustard in aqueous solution. Biochemical Pharmacology. 25(21). 2347–2350. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. G. WALLACE Breakdown of academic impact, for papers by Robert J. Weinkam Breakdown of academic impact, for papers by Leif Nørskov‐Lauritsen Breakdown of academic impact, for papers by Kurt Eger Breakdown of academic impact, for papers by Micheal D. Gaul Breakdown of academic impact, for papers by Shanthi R. Paranawithana Breakdown of academic impact, for papers by Eva Altmann Breakdown of academic impact, for papers by T. Brian H. McMurry Breakdown of academic impact, for papers by Nada Zein Breakdown of academic impact, for papers by Jeffrey R. Spencer
Rankless by CCL
2026